

Amin M Alousi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3592092/publications.pdf>

Version: 2024-02-01

188
papers

5,024
citations

117625

34
h-index

106344

65
g-index

189
all docs

189
docs citations

189
times ranked

5206
citing authors

#	ARTICLE	IF	CITATIONS
1	Donor clonal hematopoiesis increases risk of acute graft versus host disease after matched sibling transplantation. <i>Leukemia</i> , 2022, 36, 257-262.	7.2	19
2	Home-Based Spirometry Telemonitoring After Allogeneic Hematopoietic Cell Transplantation: Mixed Methods Evaluation of Acceptability and Usability. <i>JMIR Formative Research</i> , 2022, 6, e29393.	1.4	1
3	Haploidentical versus Matched Unrelated versus Matched Sibling Donor Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 395.e1-395.e11.	1.2	6
4	Dosing a synbiotic of human milk oligosaccharides and B.Ânfantis leads to reversible engraftment in healthy adult microbiomes without antibiotics. <i>Cell Host and Microbe</i> , 2022, 30, 712-725.e7.	11.0	32
5	Cytogenetics and Blast Count Determine Transplant Outcomes in Patients with Active Acute Myeloid Leukemia. <i>Acta Haematologica</i> , 2021, 144, 74-81.	1.4	2
6	Azithromycin may increase hematologic relapse rates in matched unrelated donor hematopoietic cell transplant recipients who receive anti-thymocyte globulin, but not in most other recipients. <i>Bone Marrow Transplantation</i> , 2021, 56, 745-748.	2.4	4
7	Fractionated busulfan myeloablative conditioning improves survival in older patients with acute myeloid leukemia and myelodysplastic syndrome. <i>Cancer</i> , 2021, 127, 1598-1605.	4.1	9
8	Post-transplantation cyclophosphamide reduces the incidence of acute graft-versus-host disease in patients with acute myeloid leukemia/myelodysplastic syndromes who receive immune checkpoint inhibitors after allogeneic hematopoietic stem cell transplantation. , 2021, 9, e001818.		14
9	Outcomes in patients with CRLF2 overexpressed acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2021, 56, 1746-1749.	2.4	5
10	Vedolizumab for Steroid Refractory Lower Gastrointestinal Tract Graft-Versus-Host Disease. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 272.e1-272.e5.	1.2	12
11	High Levels of Common Cold Coronavirus Antibodies in Convalescent Plasma Are Associated With Improved Survival in COVID-19 Patients. <i>Frontiers in Immunology</i> , 2021, 12, 675679.	4.8	19
12	Acute graft-versus-host disease is the foremost cause of late nonrelapse mortality. <i>Bone Marrow Transplantation</i> , 2021, 56, 2005-2012.	2.4	11
13	Impact of Cell of Origin Classification on Survival Outcomes after Autologous Transplantation in Relapsed/Refractory Diffuse Large B Cell Lymphoma. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 404.e1-404.e5.	1.2	3
14	Eltrombopag for Post-Transplantation Thrombocytopenia: Results of Phase II Randomized, Double-Blind, Placebo-Controlled Trial. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 430.e1-430.e7.	1.2	18
15	Guidelines for the Prevention and Management of Graft-versus-Host Disease after Cord Blood Transplantation. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 540-544.	1.2	11
16	Myeloablative Fractionated Busulfan With Fludarabine in Older Patients: Long Term Disease-Specific Outcomes of a Prospective Phase II Clinical Trial. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 913.e1-913.e12.	1.2	6
17	Outcomes of Second Allogeneic Hematopoietic Cell Transplantation for Patients With Acute Myeloid Leukemia. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 689-695.	1.2	14
18	Third-Party BK Virus-Specific Cytotoxic T Lymphocyte Therapy for Hemorrhagic Cystitis Following Allotransplantation. <i>Journal of Clinical Oncology</i> , 2021, 39, 2710-2719.	1.6	32

#	ARTICLE	IF	CITATIONS
19	Black multiple myeloma patients undergoing upfront autologous stem cell transplant have similar survival outcomes compared to Whites: A propensity score matched analysis. American Journal of Hematology, 2021, 96, E455-E457.	4.1	3
20	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: III. The 2020 Treatment of Chronic GVHD Report. Transplantation and Cellular Therapy, 2021, 27, 729-737.	1.2	29
21	Initial therapy for chronic graft-versus-host disease: analysis of practice variation and failure-free survival. Blood Advances, 2021, 5, 4549-4559.	5.2	8
22	Bone Marrow versus Peripheral Blood Grafts for Haploidentical Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide. Transplantation and Cellular Therapy, 2021, 27, 1003.e1-1003.e13.	1.2	10
23	Nonrelapse mortality among patients diagnosed with chronic GVHD: an updated analysis from the Chronic GVHD Consortium. Blood Advances, 2021, 5, 4278-4284.	5.2	36
24	Randomized phase II trial of extracorporeal phototherapy and steroids vs. steroids alone for newly diagnosed acute GVHD. Bone Marrow Transplantation, 2021, 56, 1316-1324.	2.4	18
25	Bacterial Prophylaxis in Patients with Acute Gvhd; Who Is at Risk for Bloodstream Infections?. Blood, 2021, 138, 2870-2870.	1.4	0
26	Optimizing Myeloablative Fractionated Busulfan, Fludarabine and Thiotepa Regimen: Results of Two Parallel Cohorts in a Phase 2 Prospective Clinical Trial. Blood, 2021, 138, 1802-1802.	1.4	0
27	Incidence and Outcomes of Toxoplasma Reactivation in Patients with Hematologic Diseases after Allogeneic Hematopoietic Stem Cell Transplantation. Blood, 2021, 138, 1779-1779.	1.4	0
28	Novel Disease Risk Model for Patients with Acute Myeloid Leukemia Receiving Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2020, 26, 197-203.	2.0	16
29	Outcome of Multiple Myeloma with Chromosome 1q Gain and 1p Deletion after Autologous Hematopoietic Stem Cell Transplantation: Propensity Score Matched Analysis. Biology of Blood and Marrow Transplantation, 2020, 26, 665-671.	2.0	21
30	A phase 3 randomized study of 5-azacitidine maintenance vs observation after transplant in high-risk AML and MDS patients. Blood Advances, 2020, 4, 5580-5588.	5.2	122
31	Composite GRFS and CRFS Outcomes After Adult Alternative Donor HCT. Journal of Clinical Oncology, 2020, 38, 2062-2076.	1.6	36
32	Optimizing the Conditioning Regimen for Hematopoietic Cell Transplant in Myelofibrosis: Long-Term Results of a Prospective Phase II Clinical Trial. Biology of Blood and Marrow Transplantation, 2020, 26, 1439-1445.	2.0	17
33	Feasibility and Reliability of Home-based Spirometry Telemonitoring in Allogeneic Hematopoietic Cell Transplant Recipients. Annals of the American Thoracic Society, 2020, 17, 1329-1333.	3.2	14
34	Significance of minimal residual disease monitoring by real-time quantitative polymerase chain reaction in core binding factor acute myeloid leukemia for transplantation outcomes. Cancer, 2020, 126, 2183-2192.	4.1	17
35	Posttransplantation cyclophosphamide improves transplantation outcomes in patients with AML/MDS who are treated with checkpoint inhibitors. Cancer, 2020, 126, 2193-2205.	4.1	33
36	Randomized multicenter trial of sirolimus vs prednisone as initial therapy for standard-risk acute GVHD: the BMT CTN 1501 trial. Blood, 2020, 135, 97-107.	1.4	56

#	ARTICLE	IF	CITATIONS
37	Idiopathic refractory ascites after allogeneic stem cell transplantation: a previously unrecognized entity. <i>Blood Advances</i> , 2020, 4, 1296-1306.	5.2	7
38	Phase II Study of CPX-351 Plus Venetoclax in Patients with Acute Myeloid Leukemia (AML). <i>Blood</i> , 2020, 136, 20-22.	1.4	8
39	Maintenance Treatment with Guadecitabine (SGI-110) in High Risk MDS and AML Patients after Allogeneic Stem Cell Transplantation. <i>Blood</i> , 2020, 136, 29-30.	1.4	1
40	Factors Associated with the Improvement of Outcomes of High-Risk Relapsed Hodgkin Lymphoma (HL) Patients Receiving High-Dose Chemotherapy (HDC) and Autologous Stem-Cell Transplantation (ASCT): The MD Anderson Cancer Center Experience. <i>Blood</i> , 2020, 136, 17-18.	1.4	0
41	Lower Risk of Graft Versus Host Disease after Exposure to Checkpoint Inhibitors with the Use of Post-Transplant Cyclophosphamide Prophylaxis. <i>Blood</i> , 2020, 136, 1-1.	1.4	0
42	Transplant Outcomes with Fludarabine and Melphalan in High Risk AML Patients By Donor Types. <i>Blood</i> , 2020, 136, 20-21.	1.4	0
43	Myeloablative Fractionated Busulfan with Fludarabine in Older Patients: Long Term Outcomes of Prospective Phase II Clinical Trial. <i>Blood</i> , 2020, 136, 10-11.	1.4	0
44	Risk of Gvhd and Survival in Patients with Acute Leukemia Who Were Bridged to Allogeneic Stem Cell Transplantation (alloSCT) with Venetoclax- Based Therapy. <i>Blood</i> , 2020, 136, 13-14.	1.4	1
45	Minimal Residual Disease Eradication with Guadecitabine (SGI-110) in the Post-Transplant Setting. <i>Blood</i> , 2020, 136, 10-11.	1.4	0
46	African-Americans Multiple-Myeloma Patients Undergoing Upfront Autologous Stem Cell Transplant Have Similar Survival Outcomes Compared to Whites: A Propensity-Score Matched Analysis. <i>Blood</i> , 2020, 136, 9-10.	1.4	1
47	Vedolizumab for Steroid Refractory Lower Gastrointestinal Tract Graft Versus Host Disease. <i>Blood</i> , 2020, 136, 39-40.	1.4	0
48	A Randomized Study of Pretransplant Conditioning Therapy for AML/MDS with Fludarabine ± Clofarabine and Once Daily IV Busulfan with Allogeneic Hematopoietic Transplantation for AML and MDS. <i>Blood</i> , 2020, 136, 37-38.	1.4	0
49	Proinflammatory Cytokine and Adipokine Levels in Adult Unrelated Marrow Donors Are Not Associated with Hematopoietic Cell Transplantation Outcomes. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 12-18.	2.0	4
50	Comparative Analysis of Calcineurin Inhibitor-Based Methotrexate and Mycophenolate Mofetil-Containing Regimens for Prevention of Graft-versus-Host Disease after Reduced-Intensity Conditioning Allogeneic Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 73-85.	2.0	35
51	Haploidentical transplantation for acute myeloid leukemia patients with minimal/measurable residual disease at transplantation. <i>American Journal of Hematology</i> , 2019, 94, 1382-1387.	4.1	20
52	HLA-DP mismatch and CMV reactivation increase risk of aGVHD independently in recipients of allogeneic stem cell transplant. <i>Current Research in Translational Medicine</i> , 2019, 67, 51-55.	1.8	13
53	Inferior Outcomes with Cyclosporine and Mycophenolate Mofetil after Myeloablative Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1744-1755.	2.0	10
54	Fecal Microbiome, Metabolites, and Stem Cell Transplant Outcomes: A Single-Center Pilot Study. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz173.	0.9	32

#	ARTICLE	IF	CITATIONS
55	Impact of T Cell Dose on Outcome of T Cell-Replete HLA-Matched Allogeneic Peripheral Blood Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1875-1883.	2.0	14
56	Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203). <i>Lancet Haematology</i> , 2019, 6, e132-e143.	4.6	200
57	Myeloablative conditioning using timed-sequential busulfan plus fludarabine in older patients with acute myeloid leukemia: long-term results of a prospective phase II clinical trial. <i>Haematologica</i> , 2019, 104, e555-e557.	3.5	6
58	Impact of Donor Type and Melphalan Dose on Allogeneic Transplantation Outcomes for Patients with Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1340-1346.	2.0	7
59	Impact of Autologous Transplantation in Patients with Multiple Myeloma with t(11;14): A Propensity-Score Matched Analysis. <i>Clinical Cancer Research</i> , 2019, 25, 6781-6787.	7.0	10
60	GRFS and CRFS in alternative donor hematopoietic cell transplantation for pediatric patients with acute leukemia. <i>Blood Advances</i> , 2019, 3, 1441-1449.	5.2	12
61	Pilot study using post-transplant cyclophosphamide (PTCy), tacrolimus and mycophenolate GVHD prophylaxis for older patients receiving 10/10 HLA-matched unrelated donor hematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2019, 54, 601-606.	2.4	24
62	Pulmonary Impairment after Respiratory Viral Infections Is Associated with High Mortality in Allogeneic Hematopoietic Cell Transplant Recipients. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 800-809.	2.0	22
63	Melphalan-based autologous transplant in octogenarian multiple myeloma patients. <i>American Journal of Hematology</i> , 2019, 94, E2-E5.	4.1	5
64	Peripheral Blood versus Bone Marrow from Unrelated Donors: Bone Marrow Allografts Have Improved Long-Term Overall and Graft-versus-Host Disease-Free, Relapse-Free Survival. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 270-278.	2.0	21
65	Impact of a novel prognostic model, hematopoietic cell transplant-composite risk (HCT-CR), on allogeneic transplant outcomes in patients with acute myeloid leukemia and myelodysplastic syndrome. <i>Bone Marrow Transplantation</i> , 2019, 54, 839-848.	2.4	24
66	Third-Party BK Virus Specific Cytotoxic T Lymphocyte Therapy for Hemorrhagic Cystitis Following Allotransplantation. <i>Blood</i> , 2019, 134, 3596-3596.	1.4	0
67	A Randomized Study of Fludarabine-Clofarabine Vs Fludarabine Alone Combined with Busulfan and Allogeneic Hematopoietic Transplantation for AML and MDS. <i>Blood</i> , 2019, 134, 257-257.	1.4	1
68	Allogeneic Hematopoietic Cell Transplantation May Improve Long-Term Outcomes in Patients with Ph-like Acute Lymphoblastic Leukemia with CRLF2 Overexpression. <i>Blood</i> , 2019, 134, 4598-4598.	1.4	0
69	Phase II Trial of High-Dose Gemcitabine/Busulfan/Melphalan with Autologous Stem Cell Transplantation for Primary Refractory or Poor-Risk Relapsed Hodgkin Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1602-1609.	2.0	15
70	Risk Stratification of Oral Potentially Malignant Disorders in Fanconi Anemia Patients Using Autofluorescence Imaging and Cytology-On-A Chip Assay. <i>Translational Oncology</i> , 2018, 11, 477-486.	3.7	11
71	Early Post-Transplant Minimal Residual Disease Assessment Improves Risk Stratification in Acute Myeloid Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1514-1520.	2.0	61
72	Donor body mass index does not predict graft versus host disease following hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2018, 53, 932-937.	2.4	1

#	ARTICLE	IF	CITATIONS
73	Pentostatin therapy for steroid-refractory acute graft versus host disease: identifying those who may benefit. <i>Bone Marrow Transplantation</i> , 2018, 53, 315-325.	2.4	9
74	Blood and Marrow Transplant Clinical Trials Network Report on the Development of Novel Endpoints and Selection of Promising Approaches for Graft-versus-Host Disease Prevention Trials. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1274-1280.	2.0	46
75	Haploidentical Transplantation for Older Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1232-1236.	2.0	64
76	New and emerging therapies for acute and chronic graft-versus-host disease. <i>Therapeutic Advances in Hematology</i> , 2018, 9, 21-46.	2.5	90
77	Influence of Age on Acute and Chronic GVHD in Children Undergoing HLA-Identical Sibling Bone Marrow Transplantation for Acute Leukemia: Implications for Prophylaxis. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 521-528.	2.0	34
78	Fludarabine with a higher versus lower dose of myeloablative timed-sequential busulfan in older patients and patients with comorbidities: an open-label, non-stratified, randomised phase 2 trial. <i>Lancet Haematology</i> , 2018, 5, e532-e542.	4.6	23
79	Response-adapted radiation therapy for newly diagnosed primary diffuse large B-cell lymphoma of the CNS treated with methotrexate-based systemic therapy. <i>Advances in Radiation Oncology</i> , 2018, 3, 639-646.	1.2	9
80	Amphiregulin modifies the Minnesota Acute Graft-versus-Host Disease Risk Score: results from BMT CTN 0302/0802. <i>Blood Advances</i> , 2018, 2, 1882-1888.	5.2	27
81	Graft-versus-host disease in recipients of male unrelated donor compared with parous female sibling donor transplants. <i>Blood Advances</i> , 2018, 2, 1022-1031.	5.2	13
82	Upper gastrointestinal acute graft-versus-host disease adds minimal prognostic value in isolation or with other graft-versus-host disease symptoms as currently diagnosed and treated. <i>Haematologica</i> , 2018, 103, 1708-1719.	3.5	8
83	Maintenance with 5-Azacytidine for Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients. <i>Blood</i> , 2018, 132, 971-971.	1.4	29
84	Impact of t(11;14) on the Outcome of Autologous Transplantation in Multiple Myeloma: A Matched-Pair Analysis. <i>Blood</i> , 2018, 132, 4607-4607.	1.4	0
85	Age over Fifty-Five Years at Diagnosis Increases Risk of Second Malignancies after Autologous Transplantation for Patients with Hodgkin Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1059-1063.	2.0	3
86	Feasibility of Lenalidomide Therapy for Persistent Chronic Lymphocytic Leukemia after Allogeneic Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1405-1410.	2.0	5
87	A randomized phase II study of standard-dose versus high-dose rituximab with BEAM in autologous stem cell transplantation for relapsed aggressive B-cell non-Hodgkin lymphomas: long term results. <i>British Journal of Haematology</i> , 2017, 178, 561-570.	2.5	12
88	Ex Vivo Mesenchymal Precursor Cell-Expanded Cord Blood Transplantation after Reduced-Intensity Conditioning Regimens Improves Time to Neutrophil Recovery. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1359-1366.	2.0	22
89	Cytogenetics and comorbidity predict outcomes in older myelodysplastic syndrome patients after allogeneic stem cell transplantation using reduced intensity conditioning. <i>Cancer</i> , 2017, 123, 2661-2670.	4.1	14
90	Improved survival after acute graft-versus-host disease diagnosis in the modern era. <i>Haematologica</i> , 2017, 102, 958-966.	3.5	79

#	ARTICLE	IF	CITATIONS
91	Relapse risk and survival in patients with FLT3 mutated acute myeloid leukemia undergoing stem cell transplantation. <i>American Journal of Hematology</i> , 2017, 92, 331-337.	4.1	39
92	Pre-transplantation minimal residual disease with cytogenetic and molecular diagnostic features improves risk stratification in acute myeloid leukemia. <i>Haematologica</i> , 2017, 102, 110-117.	3.5	54
93	Clofarabine Plus Busulfan is an Effective Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Lymphoblastic Leukemia: Long-Term Study Results. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 285-292.	2.0	24
94	Impact of Fluid Overload as New Toxicity Category on Hematopoietic Stem Cell Transplantation Outcomes. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 2166-2171.	2.0	34
95	Post-transplantation cyclophosphamide versus conventional graft-versus-host disease prophylaxis in mismatched unrelated donor haematopoietic cell transplantation. <i>British Journal of Haematology</i> , 2016, 173, 444-455.	2.5	61
96	Long-Term Outcomes after Treatment with Clofarabine±Fludarabine with Once-Daily Intravenous Busulfan as Pretransplant Conditioning Therapy for Advanced Myeloid Leukemia and Myelodysplastic Syndrome. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1792-1800.	2.0	16
97	Double epigenetic modulation of high-dose chemotherapy with azacitidine and vorinostat for patients with refractory or poor-risk relapsed lymphoma. <i>Cancer</i> , 2016, 122, 2680-2688.	4.1	48
98	Gemcitabine, Fludarabine, and Melphalan for Reduced-Intensity Conditioning and Allogeneic Stem Cell Transplantation for Relapsed and Refractory Hodgkin Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1333-1337.	2.0	19
99	IL-10+ regulatory B cells are enriched in cord blood and may protect against cGVHD after cord blood transplantation. <i>Blood</i> , 2016, 128, 1346-1361.	1.4	81
100	Specific combinations of donor and recipient KIR-HLA genotypes predict for large differences in outcome after cord blood transplantation. <i>Blood</i> , 2016, 128, 297-312.	1.4	54
101	Results of a 2-arm, phase 2 clinical trial using post-transplantation cyclophosphamide for the prevention of graft-versus-host disease in haploidentical donor and mismatched unrelated donor hematopoietic stem cell transplantation. <i>Cancer</i> , 2016, 122, 3316-3326.	4.1	75
102	Hematopoietic stem cell transplantation. , 2016, , 440-451.		1
103	The role of the gastrointestinal microbiome in infectious complications during induction chemotherapy for acute myeloid leukemia. <i>Cancer</i> , 2016, 122, 2186-2196.	4.1	121
104	Pure Red Cell Aplasia in Major ABO-Mismatched Allogeneic Hematopoietic Stem Cell Transplantation Is Associated with Severe Pancytopenia. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 961-965.	2.0	15
105	Treatment with Hypomethylating Agents before Allogeneic Stem Cell Transplant Improves Progression-Free Survival for Patients with Chronic Myelomonocytic Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 47-53.	2.0	58
106	Double umbilical cord blood transplant is effective therapy for relapsed or refractory Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2016, 57, 1607-1615.	1.3	17
107	Ifosfamide, carboplatin, etoposide with or without bortezomib in patients with relapsed/refractory Hodgkin lymphoma: results of a randomized phase II trial. <i>Leukemia and Lymphoma</i> , 2016, 57, 445-447.	1.3	5
108	Rituximab Combined with BEAM and Autologous Stem Cell Transplantation for Older Patients with Relapsed Aggressive B-Cell Lymphomas. <i>Blood</i> , 2016, 128, 2270-2270.	1.4	6

#	ARTICLE	IF	CITATIONS
109	Comparable Outcomes of Therapy-Related and De Novo Myelodysplastic Syndrome after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2016, 128, 2276-2276.	1.4	0
110	Unrelated Male Donors Versus Sibling Parous Female Donors: Impact on Transplant-Related Outcomes. <i>Blood</i> , 2016, 128, 70-70.	1.4	0
111	Implementation of a Pan-Genomic Approach to Investigate Holobiont-Infecting Microbe Interaction: A Case Report of a Leukemic Patient with Invasive Mucormycosis. <i>PLoS ONE</i> , 2015, 10, e0139851.	2.5	47
112	Tacrolimus versus Cyclosporine after Hematopoietic Cell Transplantation for Acquired Aplastic Anemia. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1776-1782.	2.0	13
113	Leukemia cell mobilization with G-CSF plus plerixafor during busulfan-fludarabine conditioning for allogeneic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2015, 50, 939-946.	2.4	32
114	Phase II Trial of Graft-versus-Host Disease Prophylaxis with Post-Transplantation Cyclophosphamide after Reduced-Intensity Busulfan/Fludarabine Conditioning for Hematological Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 906-912.	2.0	35
115	A prognostic score for acute graft-versus-host disease based on biomarkers: a multicentre study. <i>Lancet Haematology</i> , 2015, 2, e21-e29.	4.6	232
116	Comparison of Survival in Patients with T Cell Lymphoma after Autologous and Allogeneic Stem Cell Transplantation as a Frontline Strategy or in Relapsed Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 855-859.	2.0	36
117	Vorinostat Combined with High-Dose Gemcitabine, Busulfan, and Melphalan with Autologous Stem Cell Transplantation in Patients with Refractory Lymphomas. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1914-1920.	2.0	46
118	A Refined Risk Score for Acute Graft-versus-Host Disease that Predicts Response to Initial Therapy, Survival, and Transplant-Related Mortality. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 761-767.	2.0	195
119	Outcomes of Grades II-IV Acute Graft-Versus-Host Disease Post-Allogeneic Hematopoietic Stem Cell Transplantation: How Much Progress Was Achieved?. <i>Blood</i> , 2015, 126, 3132-3132.	1.4	1
120	Fluid Overload As New Toxicity Category Has a Strong Impact on Non Relapse Mortality and Survival in Allogeneic Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2015, 126, 4321-4321.	1.4	2
121	A Bayesian, Phase II Randomized Trial of Extracorporeal Photopheresis (ECP) Plus Steroids Versus Steroids-Alone in Patients with Newly Diagnosed Acute Graft Vs. Host Disease (GVHD): The Addition of ECP Improves Gvhd Response and the Ability to Taper Steroids. <i>Blood</i> , 2015, 126, 854-854.	1.4	5
122	Similar Transplantation Outcomes for Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients with Haploidentical versus 10/10 Human Leukocyte Antigen-Matched Unrelated and Related Donors. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1975-1981.	2.0	207
123	Cytogenetics, Donor Type, and Use of Hypomethylating Agents in Myelodysplastic Syndrome with Allogeneic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1618-1625.	2.0	46
124	The Effect of Peritransplant Minimal Residual Disease in Adults With Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, 319-326.	0.4	55
125	Lenalidomide-Induced Graft-Vs.-Leukemia Effect in a Patient With Chronic Lymphocytic Leukemia Who Relapsed After Allogeneic Stem Cell Transplant. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, e105-e109.	0.4	8
126	The Development of a Myeloablative, Reduced-Toxicity, Conditioning Regimen for Cord Blood Transplantation. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, e1-e5.	0.4	21

#	ARTICLE	IF	CITATIONS
127	Phase 3 clinical trial of steroids/mycophenolate mofetil vs steroids/placebo as therapy for acute GVHD: BMT CTN 0802. <i>Blood</i> , 2014, 124, 3221-3227.	1.4	92
128	Graft-versus-Host Disease: State of the Science. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, S102-S108.	2.0	17
129	Lymphocyte Phenotype during Therapy for Acute Graft-versus-Host Disease: A Brief Report from BMT-CTN 0302. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 481-485.	2.0	6
130	Prior Hypomethylating Agents Or Chemotherapy Does Not Improve The Outcome Of Allogeneic Hematopoietic Transplantation For High Risk MDS. <i>Blood</i> , 2013, 122, 305-305.	1.4	1
131	Reduced-Intensity Conditioning (RIC) and Allogeneic Stem Cell Transplantation (allo-SCT) For Relapsed/Refractory Hodgkin Lymphoma (HL) In The Brentuximab Vedotin Era: Favorable Overall and Progression-Free Survival (OS/PFS) With Low Transplant-Related Mortality (TRM). <i>Blood</i> , 2013, 122, 410-410.	1.4	5
132	Comparable Outcomes After Sibling and Matched Unrelated Donor Allogeneic Hematopoietic Cell Transplantations (HCT) In Adult Acute Lymphoblastic Leukemia (ALL) With First Complete Remission (CR). <i>Blood</i> , 2013, 122, 2142-2142.	1.4	0
133	Acute graft-versus-host disease biomarkers measured during therapy can predict treatment outcomes: a Blood and Marrow Transplant Clinical Trials Network study. <i>Blood</i> , 2012, 119, 3854-3860.	1.4	163
134	Graft-versus-host disease. <i>Journal of the American Academy of Dermatology</i> , 2012, 66, 535.e1-535.e16.	1.2	76
135	Improved Early Outcomes Using a T Cell Replete Graft Compared with T Cell Depleted Haploidentical Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 1835-1844.	2.0	227
136	A Matched Controlled Analysis of Post-Transplant Cyclophosphamide (CY) Versus Tacrolimus and Mini-Dose Methotrexate in Matched Sibling and Unrelated Donor Transplant Recipients Receiving Reduced-Intensity Conditioning: Post-Transplant CY Is Associated with Higher Rates of Acute Gvhd. <i>Blood</i> , 2012, 120, 4200-4200.	1.4	5
137	Sequential Treatment After Allogeneic Stem Cell Transplantation for Chronic Myelogenous Leukemia.. <i>Blood</i> , 2012, 120, 3129-3129.	1.4	1
138	Mesenchymal stem cells in ex vivo cord blood expansion. <i>Best Practice and Research in Clinical Haematology</i> , 2011, 24, 83-92.	1.7	57
139	Clofarabine ± Fludarabine with Once Daily i.v. Busulfan as Pretransplant Conditioning Therapy for Advanced Myeloid Leukemia and MDS. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 893-900.	2.0	93
140	Prophylaxis of Graft-Versus-Host Disease in Unrelated Donor Transplantation With Pentostatin, Tacrolimus, and Mini-Methotrexate: A Phase I/II Controlled, Adaptively Randomized Study. <i>Journal of Clinical Oncology</i> , 2011, 29, 294-302.	1.6	31
141	Pleuropericarditis, obliterative bronchiolitis and lymphocytic interstitial pneumonitis after allogeneic haematopoietic stem cell transplantation. <i>BMJ Case Reports</i> , 2011, 2011, bcr1120103488-bcr1120103488.	0.5	3
142	12-Year Experience with High-Dose Rituximab-Containing Autologous Stem Cell Transplantation for SOX11-Positive Mantle Cell Lymphoma Patients in First Remission: Emerging Lymphoma-Free Survival Plateau After 3 Years,. <i>Blood</i> , 2011, 118, 4138-4138.	1.4	0
143	Sequential Therapy with Allogeneic Transplant Followed by Low-Dose Azacitidine for CML Patients That Failed Multiple Tyrosine Kinase Inhibitors. <i>Blood</i> , 2011, 118, 3106-3106.	1.4	0
144	Nonmyeloablative Allogeneic Conditioning with Bendamustine in Combination with Fludarabine and Rituximab for Lymphoid Malignancies: Immunosuppression without Myelosuppression and without Acute Gvhd. <i>Blood</i> , 2011, 118, 894-894.	1.4	2

#	ARTICLE	IF	CITATIONS
145	Allogeneic Hematopoietic Stem Cell Transplantation for Myelofibrosis: PK Guided IV Busulfan Dose Intensity Results in Improved Event Free Survival. <i>Blood</i> , 2011, 118, 2006-2006.	1.4	0
146	Autologous and Allogeneic Stem Cell Transplantation for T-Cell Lymphoma: The M.D. Anderson Cancer Center Experience. <i>Blood</i> , 2011, 118, 4118-4118.	1.4	4
147	The role of B cell depleting therapy in graft versus host disease after allogeneic hematopoietic cell transplant. <i>Leukemia and Lymphoma</i> , 2010, 51, 376-389.	1.3	34
148	Mycophenolate Pharmacokinetics and Association with Response to Acute Graft-versus-Host Disease Treatment from the Blood and Marrow Transplant Clinical Trials Network. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 421-429.	2.0	32
149	Graft-versus-Host Disease Treatment: Predictors of Survival. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 1693-1699.	2.0	89
150	Outcome In Follicular Lymphoma (FL) Patients (pts) Relapsing After Autologous Stem Cell Transplantation (ASCT): Allografting Vs. Conventional Therapy. <i>Blood</i> , 2010, 116, 3510-3510.	1.4	0
151	Early Mixed Chimerism After Allogeneic Stem Cell Transplantation with the Reduced-Toxicity IV Busulfan-Fludarabine (BuFlu) Regimen Does Not Independently Affect Long-Term Prognosis for Patients with AML/MDS. <i>Blood</i> , 2010, 116, 3446-3446.	1.4	0
152	Reduced Intensity Conditioning Combined with Post-Transplant Cyclophosphamide for Graft Vs. Host Disease Prophylaxis In Older-Aged or Medically Frail Patients with Advanced Hematological Malignancies. <i>Blood</i> , 2010, 116, 2341-2341.	1.4	0
153	A Phase III Study of Infliximab and Corticosteroids for the Initial Treatment of Acute Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 1555-1562.	2.0	104
154	Etanercept, mycophenolate, denileukin, or pentostatin plus corticosteroids for acute graft-versus-host disease: a randomized phase 2 trial from the Blood and Marrow Transplant Clinical Trials Network. <i>Blood</i> , 2009, 114, 511-517.	1.4	217
155	Autologous Transplantation for Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL). <i>Blood</i> , 2009, 114, 2310-2310.	1.4	1
156	Autologous Stem Cell Mobilization with Cytokines and in-Vivo Alemtuzumab in Patients with T-Cell Non-Hodgkin's Lymphoma (T-NHL). <i>Blood</i> , 2009, 114, 3213-3213.	1.4	0
157	A Randomized Phase II Trial of High-Dose Melphalan, Ascorbic Acid and Arsenic Trioxide with or without Bortezomib in Multiple Myeloma. <i>Blood</i> , 2009, 114, 2309-2309.	1.4	0
158	Outcome of IgD Myeloma After Autologous Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2009, 114, 4354-4354.	1.4	1
159	Durable Remission with Salvage Autotransplants in Patients with Multiple Myeloma. <i>Blood</i> , 2009, 114, 1227-1227.	1.4	0
160	The Impact of Pre-Stem Cell Transplant Ferritin Level on Late Transplant Complications: An Analysis to Determine the Potential Role of Iron Overload on Late Transplant Outcomes. <i>The Internet Journal of Hematology</i> , 2009, 7, .	0.1	0
161	Disease staging with positron emission tomography or gallium scanning and use of rituximab predict outcome for patients with diffuse large B-cell lymphoma treated with autologous stem cell transplantation. <i>British Journal of Haematology</i> , 2008, 142, 786-792.	2.5	25
162	Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab. <i>Blood</i> , 2008, 111, 5530-5536.	1.4	294

#	ARTICLE	IF	CITATIONS
163	A Randomized Phase II Trial of High-Dose Melphalan, Ascorbic Acid and Arsenic Trioxide with or without Bortezomib in Multiple Myeloma. Blood, 2008, 112, 3320-3320.	1.4	2
164	Prognostic Factors after Nonmyeloablative Allogeneic Stem Transplantation (NST) in Chronic Lymphocytic Leukemia (CLL): Expression of P53 May Not Predict Survival.. Blood, 2008, 112, 1128-1128.	1.4	0
165	Rituximab Containing Autologous Stem Cell Transplantation May Be Curative in Mantle Cell Lymphoma for Patients in First Remission, but Not for Patients with Recurrent Disease.. Blood, 2008, 112, 1142-1142.	1.4	0
166	Reduced-Intensity Regimens for Allogeneic Stem Cell Transplantation Improve the Outcome in Advanced Multiple Myeloma. Blood, 2008, 112, 3298-3298.	1.4	0
167	Platelet Recovery Prior to Stem Cell Transplantation Predicts for Post- Transplant Outcomes in Patients with AML. Blood, 2008, 112, 3000-3000.	1.4	0
168	High Prevalence of Vitamin D Deficiency in Allogeneic Stem Cell Transplant Recipients.. Blood, 2008, 112, 2138-2138.	1.4	0
169	An Analysis of the Costs Associated with Peripheral Blood Hematopoietic Progenitor Cell Mobilization, Collection and Cryopreservation in Patients with Lymphomas Undergoing Autologous Stem Cell Transplantation. Blood, 2008, 112, 2377-2377.	1.4	0
170	Donor Type Impacts the Incidence of Severe Acute but Not Chronic Graft- Versus-Host Disease (GVHD) after Reduced Toxicity Conditioning and Allogeneic Stem Cell Transplantation (ASCT) for Treatment of AML/MDS.. Blood, 2008, 112, 2227-2227.	1.4	0
171	Addition of Umbilical Cord Blood (UCB) Unit to Reduced Intensity Conditioning (RIC) Regimen to Augment Graft Versus Tumor (GVT) in Patients (pts) with Advanced Hematologic Malignancies. Blood, 2008, 112, 3297-3297.	1.4	0
172	Regulatory and Naïve T Cells in Unmanipulated Donor Grafts Are Not Associated with Acute Graft Vs Host Disease in Matched Sibling Transplants for AML. Blood, 2008, 112, 719-719.	1.4	0
173	Busulfan and Fludarabine Conditioning Regimen Negates the Impact of Comorbidity Score on Nonrelapse Mortality in Patients with AML/MDS. Blood, 2008, 112, 799-799.	1.4	0
174	Zevalin®/BEAM/Rituximab vs BEAM/Rituximab and Autologous Stem Cell Transplantation (ASCT) for Relapsed Chemosensitive Diffuse Large B-Cell Lymphoma (DLBCL): Impact of the IPI and PET Status.. Blood, 2007, 110, 620-620.	1.4	5
175	Autotransplantation in Patients with Multiple Myeloma and Concurrent Renal Failure Is Safe and Feasible and Associated with Recovery of Renal Function in > 30% of Patients.. Blood, 2007, 110, 5126-5126.	1.4	0
176	Chemotherapy with Granulocyte Colony Stimulating Factor (G-CSF) Alone Versus Granulocyte Colony Stimulating Factor (G-CSF) Plus Granulocyte-Macrophage Stimulating Factor (GM-CSF) for Hematopoietic Progenitor Cell Mobilization in Patients with Relapsed Non-Hodgkin's Lymphomas (NHLs).. Blood, 2007, 110, 1900-1900.	1.4	0
177	A Non-Myeloablative Regimen of Fludarabine and Melphalan Is Safe and Well Tolerated for Allogeneic Transplantation in Multiple Myeloma.. Blood, 2007, 110, 3032-3032.	1.4	1
178	Mismatches in Low Expression HLA Class II Loci and MIC-A in Unrelated Donor Hematopoietic Stem Cell Transplantation (HSCT).. Blood, 2007, 110, 3050-3050.	1.4	0
179	A Comparison of 1 Antigen-Mismatched Related and Matched Unrelated Transplants.. Blood, 2007, 110, 3051-3051.	1.4	0
180	Hepatitis C (HC) Virus Infection Is Associated with Worse Survival after Allogeneic Hematopoietic Stem Cell Transplantation (alloSCT) for Hematological Malignancies.. Blood, 2007, 110, 48-48.	1.4	0

#	ARTICLE	IF	CITATIONS
181	Cardiac Toxicity and Non-Relapse Mortality in Patients with Low Left Ventricular Ejection Fraction Undergoing Stem Cell Transplantation.. Blood, 2007, 110, 3002-3002.	1.4	0
182	Risk Factors for Response after Initial Therapy for Acute Graft-Versus-Host-Disease (aGVHD).. Blood, 2007, 110, 5015-5015.	1.4	0
183	Reduced-intensity conditioning allogeneic hematopoietic stem cell transplantation. Clinical Advances in Hematology and Oncology, 2007, 5, 560-70.	0.3	13
184	Arsenic Trioxide with Ascorbic Acid and High-Dose Melphalan for Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma.. Blood, 2006, 108, 3090-3090.	1.4	1
185	Autologous Stem Cell Transplantation for Elderly Patients with Multiple Myeloma.. Blood, 2006, 108, 5422-5422.	1.4	0
186	Deletion of the Short Arm of Chromosome 1 (del 1p) Is the Strongest Predictor of Poor Outcome in Myeloma Patients Undergoing an Autotransplant.. Blood, 2006, 108, 3101-3101.	1.4	0
187	Hematopoietic Progenitor Cells: Allogeneic Transplantation. , 0, , 542-558.		1
188	A randomized phase III study of pretransplant conditioning for AML/MDS with fludarabine and once daily IV busulfan±clofarabine in allogeneic stem cell transplantation. Bone Marrow Transplantation, 0, , .	2.4	3